Indivior Pharmaceuticals (INDV) EV to CFO (2024 - 2026)

Indivior Pharmaceuticals has reported EV to CFO for 3 years, with the latest figure at 20.18 in Q2 2026.

• On a quarterly basis, EV to CFO rose 139.84% year-over-year to 20.18 in Q2 2026; TTM through Jun 2026 was 115.5, a 1994.47% decrease from a year earlier, with the FY2025 full-year figure at 158.98, down 565.49% from the prior year.
• EV to CFO was 20.18 for Q2 2026 at Indivior Pharmaceuticals, up from 393.46 in the prior quarter.
• The five-year high for EV to CFO was 643.5 in Q3 2024, with the low at 393.46 in Q1 2026.
• Average EV to CFO over 3 years is 7.8, with a median of 5.51 recorded in 2025.
• The largest YoY upside for EV to CFO was 139.84% in 2026 against a maximum downside of 3716.17% in 2026.
• Over 3 years, EV to CFO stood at 72.32 in 2024, then soared by 73.14% to 19.42 in 2025, then soared by 203.88% to 20.18 in 2026.
• The last three EV to CFO figures came in at 20.18 (Q2 2026), 393.46 (Q1 2026), and 19.42 (Q4 2025), per Business Quant data.